|
Founded in 1995 with a vision to establish a company that would in turn help create a healthier China, Simcere Pharmaceutical Group has become a leading manufacturer and supplier of drugs in the rapidly growing China pharmaceutical market, we now have seven certified Good Manufacturing Practices ("GMP") manufacturing facilities and three research and development center and over 4,000 employees. Now Simcere has more than 20 Innovative Pharmaceuticals which are under development, and they all have independent intellectual property rights. In 2010, From them we submitted five clinical trial applications to the SFDA.
In 2007 Simcere successfully landed the New York Stock Exchange (ticker symbol SCR) as the first one in mainland China's chemical and biological drugs NYSE-listed company. |